ARCHIVES

Changes Put Pharma In Control Of Trials Traditionally Conducted By Academics.

This article is from The Cancer Letter archive.

Vol. 36 No. 11 | March 26, 2010

Download PDF Visit The Full Archive

Related Articles

Inhibitor Reduces Spleen Size By 35 Percent or More in Phase III

June 28, 2013

Clinical Trials Approved by NCI CTEP Last Month

August 26, 2011

ODAC Clarifies Standards for Maintenance In Ovarian Cancer; Nixes Olaparib in 11-2 Vote

June 27, 2014

Senate Committee Investigating Pharma’s “Educational Grants.”

January 20, 2006

NCAB Action On Diet FIT “Not Cavalier,” Chairman Korn Says

November 10, 1989

GM Corp, to Reimburse Marrow Transplants for Breast Cancer

March 15, 1996